Effect of race and hypertension on plasma amylin concentrations

Hypertension

Volumn 27, Issue 6, 1996, Pages 1273-1276

  Dimsdale, Joel E ^a,c   Kolterman, Orville ^b   Koda, Joy ^b   Nelesen, Richard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

amylin; glucose; insulin; peptides; race

Indexed keywords

AMYLIN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE;

EID: 0029947970     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.27.6.1273     Document Type: Article

References (21)

1. Welborn TA, Brechenridge A, Rubinstein AH, Dollery CT, Fraser TR. Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet. 1966;1:1336-1337.
2. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Pedrinclli R, Brandi L, Bceilacqua S. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350-357.
3. Saad MF, Lillioja S, Nyomba BL, Castillo C, Ferraro R, De Gregorio M, Ravussin E, Knowler WC, Bennett P, Howard B. Racial difference in the relation between blood pressure and insulin resistance. N Engl J Med. 1991;324:733-739.
4. Williams B. Insulin resistance: the shape of things to come. Lancet. 1994;344:521-524.
5. Liang C-S, Doherty JU, Faillace R, Maekawa K, Arnold S, Gavras H, Hood BW Jr. Insulin infusion in conscious dogs: effects on systemic and coronary hemodynamics, regional blood flows, and plasma catecholamines. J Clin Invest. 1982;69:1321-1336.
6. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes. 1981;30:219-225.
7. Young AA, Rink TJ, Vine W, Gedulin B. Amylin and syndrome X. Drug Dev Res. 1994;32:90-99.
8. Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark P, Schneider A, Hales C, Yudkin J. The relationship of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia. 1990;33:532-537.
9. Westermark P, Wernstedt C, O'Brien TD, Hayden DW, Johnson KH. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am J Pathol. 1987;127:414-417.
10. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA. 1987;84:8628-8632.
11. Peiro E, Degano P, Silvestre RA, Marco J. Inhibition of insulin release by amylin is not mediated by changes in somatostatin output. Life Sci. 1991;49:761-765.
12. Frontoni S, Choi SB, Banduch D, Rossetti L. In vivo insulin resistance induced by amylin primarily through inhibition of insulin-stimulated glycouen synthesis in skeletal muscle. Diabetes. 1991;40:568-573.
13. Wookey P, Berka J, Rumble J, Kelly D, Du H, Cooper M. Amylin binding sites in rat kidney and stimulation of plasma renin activity: characterization using antagonists. Diabetologia. 1994;37:A116. Abstract.
14. Kautaky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhausi W, Prager R. Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetolagia. 1994;37:188-194.
15. Harris MI. Non-insulin dependent diabetes mellitus in black and white Americans. Diabetes Metab Rev. 1990;6:71-90.
16. Hall WD, Saunders E, Shulman N, eds. Hypertension in Blacks: Epidemiology, Pathophysiology, and Treatment. Chicago, Ill: Year Book Medical Publishers Inc; 1985.
17. Morgan C, Lazarow A. Immunoassay of insulin: two antibody systems. Plasma levels of normal, subdiabetic and diabetic rats. Diabetes. 1963;12:115-126.
18. Rittenhouse J, Janes SM, Bierle JR, Park DM, Phelps JL, Koda JE. Isolation and characterization of human amylin. Protein Sci. 1994;3:66. Abstract.
19. Percy AJ, Trainor D, Rittenhouse J, Janes S, Koda JE. Sensitive two-site enzyme immunoassays for amylin and amylin-like peptides in human plasma. Diabetologia. 1994;37(suppl 1):A117. Abstract.
20. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039-1057.
21. Kailasam M, Fineman M, Koda J, Parmer R, O'Connor D, Circulating amylin in human essential hypertension: racial differences and early elevations in subjects at genetic risk of hypertension. J Invest Med. 1995;43(suppl 2):266A. Abstract.